{
    "nctId": "NCT00050141",
    "briefTitle": "Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer",
    "officialTitle": "A Randomised, Blinded, Phase 2 Study of Letrozole Plus the Farnesyl Transferase Inhibitor ZARNESTRA TM (R115777) and Letrozole Plus Placebo in the Treatment of Advanced Breast Cancer After Antiestrogen Therapy.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 121,
    "primaryOutcomeMeasure": "Comparisons between the two treatment groups will be made for patients who have achieve a confirmed Complete Response (CR) or Partial Response (PR).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced, inoperable loco-regionally-recurrent, or metastatic breast cancer\n* Estrogen and/or progesterone positive disease\n* Progression of disease after antiestrogen therapy\n* Measurable disease\n* Postmenopausal\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n\nExclusion Criteria:\n\n* Previous endocrine therapy, other than antiestrogen therapy\n* More than 1 prior chemotherapy regimen\n* Previous therapy with farnesyl transferase inhibitor\n* Presence of rapidly progressive, life-threatening metastases\n* Concomitant anticancer treatment\n* Other malignancy within the past 5 years\n* Symptomatic peripheral neuropathy.",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}